Moderna’s vaccine is more effective than Pfizer in preventing infections and hospitalizations

A study reveals a lower number of infections by COVID-19 and a lower risk of hospitalization in those who received the Moderna vaccine compared to Pfizer-BioNTech.

A new study by researchers at Case Western Reserve University School of Medicine in the United States has revealed that people who receive Moderna’s COVID-19 vaccine have more than those who receive Pfizer-BioNTech’s .

The research, published in the scientific journal ‘Journal of the American Medical Association’, has also determined that those who received the Moderna vaccine were less likely to be hospitalized. The study examines SARS-CoV-2 infections, hospitalizations and

The research analyzed the electronic health records of more than 637,000 fully vaccinated patients from 63 health organizations across the United States, spanning various geographic areas, ages, races and ethnicities, income levels, and insurance groups.

The data included COVID-19 infections that occurred in vaccinees between July and November 2021, when Delta accounted for nearly all cases. Incidents of breakthrough infections were included if the person had not previously been infected with COVID-19 or had received a booster vaccination.

The team took into account demographics, social determinants of health, transplants, and comorbidities. We also compared the rates of

The results show that the monthly incidence rate of ruptured cases was higher in those who received the Pfizer-BioNTech vaccine, compared to that of Moderna.

For example, the data showed 2.8 cases in those vaccinated with Pfizer-BioNTech, compared to 1.6 cases per 1,000 people in November 2021.

The 60-day hospitalization rate was 12.7 percent for Moderna recipients and 13.3 percent for Pfizer-BioNTech recipients. However, no significant difference in mortality rates was seen between those who received the Moderna and Pfizer-BioNTech vaccines.

“Although there is a difference in terms of infections, both vaccines are highly protective against SARS-COV2 infection and, especially, against ”, commented one of those responsible for the work, Pamela B. Davis.